| 词条 | Intercell |
| 释义 |
| name = Intercell AG | logo = Intercell.svg | logo_size = 120px | type = Aktiengesellschaft | traded_as = WBAG: ICLL OTCQX: INRLY | foundation = 1998 | founder = | location_city = Vienna | location_country = Austria | locations = | area_served = | key_people = Thomas Lingelbach (CEO), Michel Gréco (Chairman of the supervisory board) | industry = Biotechnology | fate = Merged with Vivalis SA | successor = Valneva SE | defunct = {{End date|2013}} | products = Development of vaccines | services = | revenue = €34.2 million (2010)[1] | operating_income = {{loss}} (€251.2 million) (2010)[1] | net_income = {{loss}} (€255.2 million) (2010)[1] | assets = €225.2 million (end 2010)[1] | equity = €121.1 million (end 2010)[1] | num_employees = 410 (average, 2010)[1] | divisions = | subsid = | homepage = {{URL|http://www.intercell.com/}} }}Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012.[2] Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.[3] It employs 400 people in Austria, Scotland and the United States. It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based Iomai, a developer of needle-free vaccination technology.[4][5] Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production. The most important projects of Intercell are:
References1. ^1 2 3 4 5 {{cite web |url=http://www.intercell.com/uploads/media/2010_Annual_Report.pdf |title=Annual Report 2010 |accessdate=3 May 2011 |publisher=Intercell |archive-url=https://web.archive.org/web/20110626181045/http://www.intercell.com/uploads/media/2010_Annual_Report.pdf |archive-date=26 June 2011 |dead-url=yes |df=dmy-all }} 2. ^{{cite web|url=https://www.fiercebiotech.com/financials/troubled-intercell-throws-towel-signs-off-on-merger-deal-vivalis|publisher=Fierce Biotech|title=Troubled Intercell throws in the towel, signs off on merger deal with Vivalis|first=John|last=Carroll|date=17 December 2012|access-date=27 January 2018}} 3. ^{{cite web|url=http://www.imp.ac.at/about-the-imp/history/|title=Research Institute of Molecular Pathology (IMP) - About the IMP > History|publisher=Research Institute of Molecular Pathology|accessdate=2009-07-25}} {{Dead link|date=November 2010|bot=H3llBot}} 4. ^{{cite web |url= https://www.reuters.com/article/idUSN1233533220080512 |title= Austrian vaccine maker Intercell buys Iomai |last= Fox |first=Maggie |last2= Grenon |first2= Andre |publisher= Reuters |date= 2008-05-12 |accessdate= 2008-08-15 |archiveurl= https://www.webcitation.org/5mVk9lZGs?url=http://www.reuters.com/article/idUSN1233533220080512 |archivedate = 2010-01-03}} 5. ^{{Citation | author = Staff | date = 1 June 2008 | title = Intercell to Acquire Iomai for $189M | periodical = Genetic Engineering & Biotechnology News | series = News: Inside Industry | publisher = Mary Ann Liebert, Inc. | volume = 28 | issue = 11 | page = 14 | url = | issn = 1935-472X }} 6. ^{{cite web|url=http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/1/back_to/news/article/intercell-announces-fda-approval-of-ixiaroR-a-vaccine-against-japanese-encephalitis-a-successf/|title=Intercell's Japanese Encephalitis Vaccine FDA approval|publisher=Medical News Today|date=2009-03-31|accessdate=2009-03-31}} {{Dead link|date=October 2010|bot=H3llBot}} 7. ^{{cite web|url=http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/1/back_to/news/article/intercell-announces-european-approval-of-new-vaccine-ixiaroR-to-prevent-japanese-encephalitis/|title=Intercell's Japanese Encephalitis Vaccine EMEA approval for Europe|publisher=Intercell|date=2009-04-02|accessdate=2009-04-02}} {{Dead link|date=October 2010|bot=H3llBot}} 8. ^{{cite web|url=http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/2/back_to/news/article/australian-authorities-tga-first-to-grant-final-product-approval-for-intercells-vaccine-to-preven/|title=Intercell's Japanese Encephalitis Vaccine Australian TGA approval|publisher=Intercell|date=2009-01-23|accessdate=2009-01-23}} {{Dead link|date=October 2010|bot=H3llBot}} 9. ^{{cite web|url=http://www.fdanews.com/newsletter/article?articleId=97461&issueId=10614|title=Intercell Hepatitis C Vaccine Meets Primary Endpoints|publisher=FDA News|date=2007-08-22|accessdate=2008-08-15}} External links
4 : Companies based in Vienna|Biotechnology companies|Technology companies established in 1998|Defunct companies of Austria |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。